Pfizer plans to acquire biopharmaceutical firm Metsera for $4.9 billion to enter the obesity drug market, gaining access to Metsera's therapies and expertise. The deal includes a premium payment per share and potential additional payments based on product development. The obesity treatment market is rapidly growing, with significant financial forecasts for the future. Teljes cikk (Euronews.com)